Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OneMedNet (ONMD) Share-based Compensation (2022 - 2025)

OneMedNet has reported Share-based Compensation over the past 4 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Share-based Compensation rose 720.44% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 223.57% year-over-year, with the annual reading at $2.0 million for FY2025, 223.57% up from the prior year.
  • Share-based Compensation was $1.5 million for Q4 2025 at OneMedNet, up from $142000.0 in the prior quarter.
  • Over five years, Share-based Compensation peaked at $1.8 million in Q4 2022 and troughed at $29000.0 in Q4 2023.
  • The 4-year median for Share-based Compensation is $207000.0 (2024), against an average of $457480.5.
  • Year-over-year, Share-based Compensation plummeted 98.4% in 2023 and then soared 720.44% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $1.8 million in 2022, then plummeted by 98.4% to $29000.0 in 2023, then skyrocketed by 524.14% to $181000.0 in 2024, then soared by 720.44% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ONMD's Share-based Compensation are $1.5 million (Q4 2025), $142000.0 (Q3 2025), and $197000.0 (Q2 2025).